Related Experiment Video

Updated: Aug 10, 2026

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
16:24

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

Selective oestrogen receptor modulation: molecular pharmacology for the millennium

A S Levenson1, V C Jordan

  • 1Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611, USA.

European Journal of Cancer (Oxford, England : 1990)
|March 11, 2000
PubMed

Insights

Tamoxifen and raloxifene knowledge enables multifunctional medicines. These drugs offer potential prevention for osteoporosis, heart disease, and cancers in high-risk postmenopausal women.

Area of Science:

  • Pharmacology and Medicine
  • Oncology
  • Endocrinology

Background:

  • Tamoxifen and raloxifene are established drugs with specific preventive actions.
  • Understanding their mechanisms has paved the way for broader applications.
  • Multifunctional medicines are emerging as a new therapeutic avenue.

Purpose of the Study:

  • To explore the potential of multifunctional medicines.
  • To identify drugs that can prevent multiple diseases in postmenopausal women.
  • To leverage existing pharmacological knowledge for broader health benefits.

Main Methods:

  • Review of existing pharmacological data on tamoxifen and raloxifene.
  • Analysis of disease mechanisms for breast cancer, osteoporosis, coronary heart disease, and endometrial cancer.
  • Identification of overlapping targets and pathways.

Main Results:

  • Tamoxifen and raloxifene exhibit distinct yet potentially combinable pharmacological profiles.
  • Multifunctional agents could address multiple risk factors simultaneously.
  • Potential for simultaneous prevention of osteoporosis, coronary heart disease, breast cancer, and endometrial cancer.

Conclusions:

  • Pharmacological insights into tamoxifen and raloxifene support the development of multifunctional medicines.
  • These novel therapies hold promise for comprehensive disease prevention in at-risk postmenopausal women.
  • Further research is warranted to develop and validate these agents.

More Related Videos

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Related Concept Videos

G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Signal Transduction: Overview01:26

Signal Transduction: Overview

Cells respond to many types of information, often through receptor proteins positioned on the membrane. They respond to chemical signals, such as hormones, neurotransmitters, and other signaling molecules, initiating a series of molecular reactions to produce an appropriate response. This is called signal transduction. Cells also coordinate different responses elicited by the same signaling molecule via mediators, allowing molecular cross-talk.
Typically, signal transduction involves three...
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...